EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Refractory thrombocytopenia after 177Lu-PSMA therapy: bone marrow infiltration (myelophthisis) versus treatment toxicity

Yasemin Aydinalp Camadan, Ertugrul Bayram, Tugba Toyran, Tolga Köseci, Isa Burak Guney, Ismail Oguz Kara, Berksoy Sahin

Scientific Reports in Medicine · 26.04.2026 · 3 (1) · 39-46

DOI: 10.37609/srinmed.63 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientific Reports in Medicine, online erschienen am 26.04.2026. Verfasst von Yasemin Aydinalp Camadan und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lutetium is a radiopharmaceutical used effectively to treat metastatic castration-resistant prostate cancer (mCRPC). Myelosuppression can occur after lutetium therapy, and it can be difficult to distinguish between treatment-related toxicity and bone marrow infiltration (myelophthisis), especially in patients with extensive bone metastases. A 60-year-old male patient with metastatic castration-resistant prostate cancer was scheduled for 177Lu-PSMA therapy after progression on docetaxel and abiraterone. Thrombocytopenia developed after the first course. At the same time, the patient developed infective endocarditis. Although platelet counts temporarily improved with infection management, severe thrombocytopenia recurred after the second 177Lu-PSMA cycle. Bone marrow biopsy revealed infiltration by prostate adenocarcinoma. It was determined that the patient's thrombocytopenia was caused by cancer infiltration of the bone marrow and the resulting myelophthisis. Hematologic toxicity is a recognized complication of 177Lu-PSMA therapy in patients with mCRPC and extensive skeletal involvement, bone marrow is essential to differentiate between effects caused by treatment and myelophthisis in cases of refractory cytopenia.

Zitieren

APA

Camadan, Y. A., Bayram, E., Toyran, T., Köseci, T., Guney, I. B., Kara, I. O., & Sahin, B. (2026). Refractory thrombocytopenia after 177Lu-PSMA therapy: bone marrow infiltration (myelophthisis) versus treatment toxicity. Scientific Reports in Medicine, 3(1), 39-46. https://doi.org/10.37609/srinmed.63

Vancouver

Camadan YA, Bayram E, Toyran T, Köseci T, Guney IB, Kara IO, et al. Refractory thrombocytopenia after 177Lu-PSMA therapy: bone marrow infiltration (myelophthisis) versus treatment toxicity. Scientific Reports in Medicine. 2026;3(1):39-46. doi:10.37609/srinmed.63

BibTeX
@article{Camadan2026,
  author = {Camadan, Yasemin Aydinalp and Bayram, Ertugrul and Toyran, Tugba and Köseci, Tolga and Guney, Isa Burak and Kara, Ismail Oguz and Sahin, Berksoy},
  title = {Refractory thrombocytopenia after 177Lu-PSMA therapy: bone marrow infiltration (myelophthisis) versus treatment toxicity},
  journal = {Scientific Reports in Medicine},
  year = {2026},
  volume = {3},
  number = {1},
  pages = {39--46},
  doi = {10.37609/srinmed.63}
}
Kostenlos starten →